NEW YORK (GenomeWeb News) – Pharmagogenomics firm DxS said today that it has signed an agreement with Amgen to market its K-RAS assay as a companion diagnostic for Amgen’s Vectibix (panitumumab) colorectal cancer therapy in the US.
 
Under the terms of the agreement, DxS’ TheraScreen K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix if approved by the US Food and Drug Administration, DxS said. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.